GRI

More prominent safety warnings about the neuropsychiatric effects of montelukast

News Healthcare & Pharma General Updates
Date: 16th Jan, 2025 Source: Therapeutic Goods Administration (TGA) Country: Australia Original Source

Brief

On December 18, 2024, the Therapeutic Goods Administration (TGA) issued an update regarding montelukast. Montelukast is a prescription medicine used to prevent and treat chronic asthma in adults and children aged 2 years and older, and for symptomatic seasonal allergic rhinitis (hay fever). The TGA added a new boxed warning and updated product information to highlight serious neuropsychiatric events, including behavioral changes, depression, and suicidal thoughts and behavior.

This content is restricted.

Highlights content goes here...

This content is restricted.

Therapeutic Goods Administration (TGA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
Deputy Minister Nel to Launch the Phuthaditjhaba Thuthuzela Care Centre
Date: 11th Apr, 2025 Source: National Prosecuting Authority Country: South Africa
News Anti-bribery and corruption General Updates
Fasatgh: BaFin warns against offers on websites fasatgh.com and fasat-gh.world
Date: 11th Apr, 2025 Source: Federal Financial Supervisory Authority (BaFin) Country: Germany
News Corporate Finance & M&A General Updates
Be careful when cuddling with pets
Date: 9th Apr, 2025 Source: Federal Office of Consumer Protection and Food Safety Country: Germany
News Consumer protection General Updates

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales